Medical Communications

The third FDA advisory panel member has quit over the approval of a controversial new Alzheimer’s drug. Biogen’s drug, aducanumab, …

A novel digital therapeutics software, DTxP, has shown statistically significant benefits for patients with chronic low back pain (CLBP) in …

Boris Johnson has announced at the G7 meeting in Cornwall that the UK will donate over 100 million surplus doses …

A Phase III study evaluating the safety and efficacy of sutimlimab in people with cold agglutinin disease (CAD) met its …

Among our ten most-read stories this week: AstraZeneca vs GSK: Cancer drug court battle could cost hundreds of millions; New …

Among our ten most-read stories this week: NICE rejects risdiplam for treating spinal muscular atrophy; The EU wants to Fine …

Novartis’s 177Lu-PSMA-617 has shown to significantly improve overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer …

Bristol Myers Squibb (BMS) has announced results from the Phase III CheckMate -648 trial in which nivolumab plus chemotherapy and …

Results from OlympiA’s Phase III trial has shown that its Olaparib (Lynparza) in the adjuvant treatment of patients with germline …

Johnson & Johnson’s interleukin-23 (IL-23) Tremfya (guselkumab) has shown positive results in Phase IIIb trials, in post-tumour necrosis factor (TNF) …

It’s been 15 years since the first biosimilar entered the market, and the impact of these drugs on the healthcare …

Before any kind of new medicine can be made available to the market, it has to go through a strictly …

Softbox Systems has appointed Sean Austerberry as its Research and Product Development Director. Sean will be responsible for all of …

Sharp has appointed Robert O’Beirn as SVP and Managing Director of its global Clinical Services business. In early 2019 Mr …

Acacia Pharma has appointed Debra Hussain as Chief Commercial Officer. She is a highly experienced commercial leader having spent over …